The highest non-severely toxic dose is a non-clinical parameter for the early development of certain anticancer pharmaceuticals. Known as HNSTD, it refers to the highest dose in a non-rodent study that results in no lethality, life-threatening toxicity, or irreversible findings. This value supports the selection of a scientifically justified starting dose for patients, but it is not a dose level determined in a clinical trial.
Non-rodent study and toxicological criterion
The HNSTD is derived from the evaluation of a non-clinical study in an appropriate non-rodent species. It does not require that no toxicity occurs at all. Rather, the decisive factor is whether the findings reach the threshold of severe toxicity: death, a life-threatening reaction, or an irreversible finding excludes the respective dose as an HNSTD.
This definition is narrower than a general description of tolerability. It requires a comprehensive toxicological assessment including severity and reversibility, not just the reporting of a laboratory value. ICH S9 normally categorizes toxicological studies in rodents and non-rodents for systemically administered small molecules. For biopharmaceuticals, the guideline refers to ICH S6(R1) regarding species selection.
Use for study initiation in oncology
ICH S9 follows a specific development framework for patients with advanced, serious malignant diseases. The goal of the starting dose there is a dose with expected pharmacological activity that can also be reasonably safely administered. All available PK, PD, and toxicity data remain relevant for this decision.
If the non-rodent is the most appropriate species, ICH S9 cites one-sixth of the HNSTD as an appropriate starting dose. This statement should not be applied to every drug development program. For immuno-agonistic biopharmaceuticals, for example, the minimum anticipated biological effect (MABEL) may be considered as a starting point. The FDA Questions and Answers on ICH S9 additionally emphasize that differences in binding affinity between animals and humans must be taken into account when applying the HNSTD.
Distinction from the clinical maximum tolerated dose
The HNSTD is determined in animal experiments prior to use in humans. It is therefore not the result of a Phase I dose escalation. Its purpose lies in bridging non-clinical findings and the initial clinical dosing proposal, not in establishing a later therapeutic dose.
In contrast, the existing maximum tolerated dose (MTD) arises in a clinical trial based on the tolerability of participants. Its name also points to a different logic: the HNSTD excludes severe toxicity in animal experiments, while the maximum tolerated dose describes a limit derived in humans. Dose-limiting toxicity can influence the determination of the clinical maximum tolerated dose, but it is also not to be equated with the HNSTD parameter.
The study design is significant for the HNSTD because the dose and schedule of non-clinical administration should be as close as possible to the intended clinical conditions. ICH S9 points out that toxicity can depend heavily on the administration schedule. A parameter from a single dose cannot, therefore, be transferred to a repeated clinical regimen without verification. Likewise, documentation of a recovery phase is important if serious findings were observed at approximately clinical exposure levels.
The HNSTD is not to be understood as the highest technically administrable dose. It requires a justified selection of dose levels and a study that allows the severity of potential findings to be identified. Its benefit lies precisely in separating severe and irreversible burden from the range that can be used for a cautious first application in humans.
The designation “non-severely toxic” therefore requires a justified distinction in the evaluation, not just the observation that animals survived the administration. Clinical relevance, severity, and reversibility of potential findings must be collectively identifiable in the toxicological report.
Relevance for clinical trials
For an oncology First-in-Human protocol, it must be transparent which non-rodent study the HNSTD originates from and why this species is relevant for the active ingredient. Clinical dose planning also requires the scaling used, the application schedule, recovery data, and the rationale regarding expected exposure. Unclear or irreversible animal findings must not disappear behind a single dose figure.
Full-service CROs like Mediconomics support oncology programs by compiling non-rodent data, coordinating the starting dose justification, and developing cohort-related escalation and stopping criteria. Clinical project management and medical writing can thus integrate the HNSTD comprehensibly into the protocol, Investigator’s Brochure, and safety committee documents.
Frequently Asked Questions (FAQ)
Does the HNSTD refer to a completely toxicity-free dose?
That is not the case. Minor or reversible findings may be present; excluded are the indications of lethality, life-threatening toxicity, and irreversibility specified in ICH S9.
In which species is the HNSTD used?
The parameter refers to non-rodents when these are the appropriate species for deriving the starting dose.
Is one-sixth of the HNSTD a general rule?
ICH S9 specifies this fraction for the described oncological context in an appropriate non-rodent species; the starting dose must still be scientifically justified.
Regulatory References
- ICH S9, Nonclinical Evaluation for Anticancer Pharmaceuticals – defines the HNSTD and specifies its use for the oncology starting dose.
- FDA, ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers – explains the application for biopharmaceuticals.
- ICH S6(R1), Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals – regulates the relevant species selection for biopharmaceuticals.